Statizoid

Health in Eastern Mediterranean (WHO region)

174 indicators covering health for Eastern Mediterranean (WHO region).

IndicatorLatest Year10-yr change Rank
ndx - number of people dying between ages x and x+n 3,497 2021 down 22.5% 3rd
Cases started on MDR-TB treatment 5,828 2024 up 70.3% 10th
Raised fasting blood glucose (>=7.0 mmol/L) 13.7 2014 up 29.2% 1st
Raised fasting blood glucose (>= 7.0 mmol/L) 11.1 2014 up 35.4% 1st
Reported number of people requiring interventions against NTDs 77.00 million 2024 down 10.2% 5th
Births attended by skilled health personnel 87.0% 2025 up 20.8% 6th
Percentage of total deaths due to NCDs overall and percentage of 25.07 2019 down 27.4% 4th
Low birth weight prevalence 15.7% 2020 unchanged 3rd
Inactivated first-dose polio vaccine (IPV1) immunization coverage 84.0% 2025 up 250.0% 9th
Low birth weight number 2,949 2020 up 4.5% 8th
Number of current cigarette smokers, estimate 72.97 million 2030 up 17.9% 5th
Reported number of children receiving antiretroviral therapy 8,200 2025 up 331.6% 6th
New or unknown treatment history cases: Pulmonary, bacteriologically 259,578 2023 up 49.2% 8th
Number of children aged 6-59 months with anaemia 36,386 2019 up 6.8% 7th
Prevalence of anaemia in children aged 6-59 months 42.7% 2019 down 8.2% 5th
HIV-positive TB patients on ART (antiretroviral therapy) 81.0% 2024 up 28.6% 8th
Treatment success rate for patients treated for MDR-TB 75.0% 2022 up 15.4% 4th
Treatment success rate: HIV-positive TB cases 78 2023 up 30.0% 6th
Polio vaccine: inactivated second or third-dose polio vaccine (IPVc) 75.0% 2025 — 7th
International Health Regulations core capacity scores, SPAR version 60 2025 — 4th
Number of reported cases of poliomyelitis by wild poliovirus 12 2023 down 63.6% 1st
Estimated number of malaria deaths 22,066 2024 up 186.8% 3rd
Number of prevalent tuberculosis cases 1.00 million 2014 unchanged 8th
Estimated malaria incidence 19.08 2024 up 130.8% 3rd
Estimated malaria mortality rate 3.79 2024 up 137.0% 3rd
Japanese encephalitis - number of reported cases 0 2025 — 7th
Number of pregnant women living with HIV who received antiretrovirals 2,100 2025 up 118.8% 7th
Neonates protected at birth against neonatal tetanus (PAB) 82.0% 2022 up 3.8% 9th
Percentage of people living with HIV who know their HIV status 41 2025 up 51.9% 7th
Percentage of people living with HIV who know their status receiving 76 2025 up 46.2% 6th
Population with basic handwashing facilities at home 79.1% 2024 up 38.9% 3rd
Tuberculosis - new and relapse cases 411,587 2011 up 169.8% 8th
Estimated number of pregnant women living with HIV needing 8,800 2025 up 41.9% 7th
Total number of notified TB cases 465,677 2014 up 94.4% 8th
Estimated number of pregnant women living with HIV 24 2025 up 60.0% 6th
Smear-positive tuberculosis treatment-success rate 88.0% 2011 up 7.3% 3rd
Insufficiently active 87.02 2016 up 0.6% 1st
Number of presumed malaria cases 2.42 million 2021 down 45.1% 3rd
Number of indigenous malaria cases 2.39 million 2021 up 134.4% 3rd
Number of confirmed malaria cases 2.39 million 2021 up 133.1% 3rd
Total number of  malaria cases 4.81 million 2021 down 11.4% 3rd
Yellow fever vaccine (YFV) immunization coverage among 1-year olds 70.0% 2025 — 1st
Number of indigenous P. falciparum malaria cases 1.51 million 2021 up 1,294.3% 3rd
Preterm birth rate 10.85 2020 up 1.6% 3rd
Preterm birth 2.05 million 2020 up 5.6% 9th
Percentage of people living with HIV receiving treatment who have 79 2025 up 8.2% 7th
Number of malaria positive cases by rapid diagnostic test 854,387 2021 up 488.9% 3rd
Treatment success rate: XDR-TB cases 74 2022 up 124.2% 1st
Confirmed cases of MDR-TB 2,249 2012 up 542.6% 11th
Number of indigenous P. vivax malaria cases 579,775 2021 up 131.1% 2nd
Number of people protected from malaria by indoor residual spraying 6.02 million 2021 up 18.2% 4th
HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) 67.0% 2014 up 204.5% 7th
Meningococcal A conjugate (MENGA) vaccine immunization coverage (%) 72.0% 2025 up 75.6% 1st
Confirmed cases of MDR-TB started treatment for MDR-TB 62.0% 2012 — 9th